Teprotumumab may improve ocular surface disease in patients with TED

Ocular surface symptoms are a common complaint for patients with thyroid eye disease (TED). Data from a new study presented at the ASOPRS 52nd Annual Fall Scientific Symposium found that teprotumumab significantly improved ocular surface disease measurements and visual functioning-related quality of life in patients with TED.

Researchers analyzed 16 patients treated with teprotumumab for 24 weeks. There was a significant improvement in the frequency and severity of dry eye symptoms in addition to lower Standardized Patient Evaluation of Eye Dryness scores (9.81 ± 5.98 vs 15.88 ± 4.47) compared to baseline. At 24 weeks, 53.33% of patients had resolution of conjunctival injection and 46.67% experienced improvement. At the same time point, 87.5% of patients had resolution of chemosis and 12.5% experienced improvement.

Schirmer test results found that overall, all eyes improved after 24 weeks compared to baseline.  In eyes with abnormally low baseline tear volumes, defined as >10 mm wetting in 5 minutes, Schirmer tear volumes were13.65 ± 10.01 at 24 weeks compared to 7.14 ± 2.73 at baseline.

In 35.71% of patients, there was improvement in the grade of meibomian gland loss from baseline to 24 weeks (46% vs 25%)

Visual functioning-related quality of life was also significantly improved at 24 weeks compared to baseline.

Reference

Lu L, et al. Effect of Teprotumumab on Ocular Surface Disease in Active Thyroid Eye Disease. Presented at: ASOPRS 52nd Annual Fall Scientific Symposium.